Glucocerebrosidase as a therapeutic target for Parkinson’s disease

P 86: CD166 as a Therapeutic Target in Autoimmune Diseases

About 3 decades ago CD6 identified as one of the first antigens expresses on the majority of T cells and a subset of B cells. CD6 regulates cellular adhesion migration across the endothelial and epithelial cells. In recent years researches indicate its role in pathogenesis of autoimmune diseases. Many researches have been done in recent years to block CD6 by CD6 mono clonal antibodies, IOR-T1 a...

“Commentary: The ageing as a therapeutic target for Alzheimer’s disease”

The Epigenome as a therapeutic target for Parkinson's disease

Parkinson's disease (PD) is a common, progressive neurodegenerative disease characterised by degeneration of nigrostriatal dopaminergic neurons, aggregation of α-synuclein and motor symptoms. Current dopamine-replacement strategies provide symptomatic relief, however their effectiveness wear off over time and their prolonged use leads to disabling side-effects in PD patients. There is therefore...

PCSK9 as a therapeutic target for cardiovascular disease

It is well recognized that the elevated plasma level of low-density lipoprotein-cholesterol (LDL-C) is a major risk factor for atherosclerosis and cardiovascular disease (CVD). Deposition of pro-atherogenic LDL-C, on the intima of arterial wall, contributes to plaque formation and atherosclerosis, which further leads to lowered blood flow to vital organs and increased risk of CVD. The most comm...

Protein Kinase D as Novel Therapeutic Target for Neurological Disease

Protein kinase D (PKD) is a novel kinase whose catalytic domain resembles calcium calmodulin kinase and its regulatory domains resemble protein kinase C. We have discovered that (1) PKD is dually regulated by the NMDA and metabotropic glutamate receptors (mGluRs). In turn, PKD regulates AMPAR recycling, especially the GluR2 subunit. (2) We have found that CNS-specific PKD1 deficient mice are vi...